Trial Profile
Immunogenicity, Reactogenicity & Safety of a Booster Dose of GSK Biologicals' DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals' DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Hib-DTP-hepatitis B vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 07 Nov 2008 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
- 11 Aug 2008 Planned number of patients changed from 340 to actual patient number 148 as reported by ClinicalTrials.gov.
- 08 May 2008 Status changed from in progress to completed.